Ionis Pharmaceuticals (NASDAQ:IONS) Issues Quarterly Earnings Results

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.66) EPS for the quarter, topping analysts' consensus estimates of ($1.12) by $0.46, RTT News reports. The business had revenue of $227.00 million during the quarter, compared to the consensus estimate of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The company's revenue for the quarter was down 30.2% compared to the same quarter last year. During the same period last year, the firm earned $0.12 earnings per share. Ionis Pharmaceuticals updated its FY 2025 guidance to EPS.

Ionis Pharmaceuticals Price Performance

NASDAQ:IONS traded down $0.36 during midday trading on Friday, hitting $32.33. 1,569,929 shares of the stock were exchanged, compared to its average volume of 1,708,983. Ionis Pharmaceuticals has a one year low of $30.23 and a one year high of $52.34. The company has a market capitalization of $5.14 billion, a price-to-earnings ratio of -10.63 and a beta of 0.34. The business has a 50-day moving average price of $33.65 and a two-hundred day moving average price of $38.36. The company has a current ratio of 8.47, a quick ratio of 8.82 and a debt-to-equity ratio of 2.12.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, EVP Patrick R. O'neil sold 6,165 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $31.62, for a total value of $194,937.30. Following the transaction, the executive vice president now owns 57,452 shares in the company, valued at approximately $1,816,632.24. The trade was a 9.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael R. Hayden purchased 5,000 shares of the firm's stock in a transaction on Monday, December 23rd. The stock was acquired at an average price of $36.22 per share, for a total transaction of $181,100.00. Following the transaction, the director now owns 35,219 shares of the company's stock, valued at $1,275,632.18. The trade was a 16.55 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 110,609 shares of company stock valued at $3,564,867 over the last quarter. Corporate insiders own 2.71% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on IONS shares. William Blair reiterated an "outperform" rating on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. Piper Sandler decreased their price target on Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. Needham & Company LLC reissued a "buy" rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday. Royal Bank of Canada reissued an "outperform" rating and issued a $70.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday. Finally, StockNews.com cut shares of Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $60.00.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.